| ★ 01.11.2026 14:35 UTC | Novo Nordisk Trades at 10 Times Earnings While Buying Back Billions in Stock. Is This the Bottom? | Motley Fool |
| ★ 31.10.2026 13:27 UTC | Eli Lilly Rallies 11% in a Week as Q3 Sales Jump 39%, “Exceeding Our Prior Expectations” | TIKR |
| ★ 31.10.2026 09:00 UTC | Eli Lilly Soars 11% in a Week on a $5.5 Billion Guidance Raise: “Beating on the Up” | TIKR |
| ★ 31.10.2026 05:12 UTC | Can Novo Nordisk (NYSE:NVO) Trade Below Fair Value On Earnings? | Simply Wall St. |
| ★ 30.10.2026 22:14 UTC | Novo Nordisk (NYSE:NVO) Could Be 61% Undervalued Following Rising GLP 1 Competition | Simply Wall St. |
| ★ 30.10.2026 17:09 UTC | Novo Nordisk (NVO) Sets New 2030 Goals As GLP 1 Competition Builds | Simply Wall St. |
| ★ 30.10.2026 15:56 UTC | Agios Sinks 18% as FDA Delays Sickle Cell Drug Decision to 2027 Despite Being “Launch-Ready” | TIKR |
| ★ 30.10.2026 15:41 UTC | Global Weight Loss Market Size, Share, Trends & Forecast (2026-2036) Featuring Novo Nordisk, Boehringer Ingelheim, Herbalife, WW Int'l, Medtronic and More | GLP-1 Drugs, Oral Therapies, Coverage, and | GlobeNewswire |
| ★ 30.10.2026 15:07 UTC | VKTX: Is a 2029 Launch for Its Obesity Drug Within Reach? | Zacks |
| ★ 30.10.2026 12:00 UTC | Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock | Zacks |
| ★ 29.10.2026 20:36 UTC | Novo Has Big Plans for 2030. Should You Buy the Stock Now? | Motley Fool |
| ★ 29.10.2026 17:42 UTC | Eli Lilly lifts revenue outlook as weight-loss shot demand soars, shares jump ▲ Guidance raised | Reuters |
| ★ 29.10.2026 17:03 UTC | Eli Lilly Soars 5% as Mounjaro and Zepbound Demand Drives $5.5 Billion Guidance Raise | TIKR |
| ★ 29.10.2026 16:11 UTC | Eli Lilly Revenue Climbs on Demand for Obesity Drugs | The Wall Street Journal |
| ★ 29.10.2026 15:30 UTC | Novo Nordisk faces tougher GLP-1 competition, Citi says | Proactive |
| ★ 29.10.2026 14:21 UTC | LLY Stock Jumps as Q3 Earnings Beat Estimates, 2026 Sales View Raised ▲ Earnings beat | Zacks |
| ★ 28.10.2026 23:15 UTC | Eli Lilly (LLY) Finds A New Lead In Diabetes As It Recasts Management | Simply Wall St. |
| ★ 28.10.2026 23:10 UTC | Novo Nordisk (CPSE:NOVO B) Stock Looks Cheap Even With Rival Pressure | Simply Wall St. |
| ★ 28.10.2026 20:12 UTC | Lilly's Reta Trounces Novo Powerhouse In Head-To-Head Test | Investor's Business Daily |
| 30.10.2026 17:33 UTC | Eli Lilly’s Next Trillion-Dollar Opportunity May Go Beyond Weight-Loss Drugs | 24/7 Wall St. |
| 30.10.2026 15:23 UTC | European Equities Traded in the US as American Depositary Receipts Fall in Friday Trading | MT Newswires |
| 29.10.2026 19:48 UTC | Why Eli Lilly’s CFO Sees Cancer Drugs as the Next Growth Drivers | Barrons.com |
| 29.10.2026 19:41 UTC | Weight-Loss Drugs Are Fueling a Beauty Boom. Two Stocks That Stand to Benefit. | Barrons.com |
| 29.10.2026 15:36 UTC | European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading | MT Newswires |
| 29.10.2026 14:59 UTC | Lilly’s Weight-Loss Machine Gets Even Bigger | Moby |
| 29.10.2026 14:03 UTC | Eli Lilly Jumps 8% as Strong Quarter Lifts Revenue Outlook; Novo Nordisk Ticks Up, Viking Therapeutics Eases ▲ Guidance raised | 24/7 Wall St. |
| 28.10.2026 19:51 UTC | Sector Update: Healthcare Stocks Rise Late Afternoon | MT Newswires |
| 28.10.2026 19:24 UTC | 16% of Employers Are Thinking About Cutting Weight-Loss Drug Coverage | 24/7 Wall St. |
StockAnalyzer